Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This past month, we saw the publication of the final, pre-specified analysis of the PROpel study, assessing abiraterone and olaparib in combination. This study was the first to be presented and published and has led the push of evidence in this disease space. This analysis showed that, in the all-comer population, overall survival was not significantly different between patients receiving abiraterone and olaparib in combination compared to abiraterone alone as first-line mCRPC treatment. These data clearly influenced the FDAs approval in a biomarker driven approach.
